title: Management strategies of dyslipidemia in the elderly: 2005.
abstract: During the past 3 years, the treatment of dyslipidemia has evolved significantly. The impact of recent trial data on management strategies in older patients is especially important, because the elderly segment of the US population continues to grow. Several clinical trials have been completed since the publication of the National Cholesterol Education Program (NCEP) Adult Treatment Panel III guidelines were published in 2001. Recent trial data strongly support the use of lipid-lowering therapy in the elderly population. Although therapeutic lifestyle changes remain highly important, supplementation with lipid-lowering therapy has been shown to reduce the risk of cardiovascular events in both primary and secondary prevention models. Compelling data noted from recent clinical trials have prompted the NCEP to publish an updated report that addresses the significant interim developments.
authors.affiliation: Grady Memorial Hospital, Atlanta, Georgia, USA. thelmy@emory.edu
authors.forename: Tarek
authors.initials: T
authors.lastname: Helmy
authors.forename: Amar D
authors.initials: AD
authors.lastname: Patel
authors.forename: Fadi
authors.initials: F
authors.lastname: Alameddine
authors.forename: Nanette K
authors.initials: NK
authors.lastname: Wenger
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002986:Clinical Trials as Topic; D050171:Dyslipidemias / Q000175:diagnosis* / Q000628:therapy*; D015577:Geriatric Assessment / Q000379:methods*; D006801:Humans; D000960:Hypolipidemic Agents / Q000145:classification / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000592:standards; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D014481:United States
chemical_list: D000960:Hypolipidemic Agents